MedElevator Войти в исследования
← Поиск публикаций
British journal of cancer · 1990

Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer.

Название и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Steward WP, Scarffe JH, Dirix LY, Chang J, Radford JA, Bonnem E, Crowther D

Аннотация

Nine patients with progressive, metastatic disease from primary carcinoma of the colon were entered into a phase I/II study using continuous intravenous infusions of granulocyte-macrophage colony-stimulating factor (GM-CSF) and high dose melphalan (120 mg m-2). GM-CSF was given alone to six patients during the first part of the study to determine a dose that would produce a peripheral leucocyte count (WCC) greater than or equal to 50 X 10(9) 1(-1) and was initially given at 3 micrograms kg-1 day-1 and escalated to 10 micrograms kg-1 day-1 after 10 days. The infusion was discontinued when the WCC exceeded 50 X 10(9) 1(-1) and after a gap of one week, melphalan was given over 30 min. GM-CSF was recommenced 8 h later and was continued until the neutrophil count had exceeded 0.5 X 10(9) 1(-1) for greater than 1 week. One patient achieved a WCC greater than 50 X 10(9) 1(-1) with GM-CSF 3 micrograms kg-1 day-1, but the other five who entered this phase of the study required dose escalation to 10 micrograms kg-1. No toxicity attributed to GM-CSF was seen. After melphalan, the median times to severe neutropenia (less than 0.5 X 10(9) 1(-1] and thrombocytopenia (greater than 20 X 10(9) 1(-1] were 6 and 9 days respectively. The median durations of neutropenia and thrombocytopenia were 14 and 10 days respectively. All patients required intensive support with a median duration of inpatient stay of 24 days. There was one treatment related death due to renal failure. One complete and two partial remissions (33% response rate) were seen but these were of short duration (median of 10 weeks). This study demonstrates that GM-CSF given by continuous intravenous infusion produces significant increments of peripheral granulocyte counts at 3 and 10 micrograms kg-1 day-1 and is not associated with any toxicity. The duration of neutropenia and thrombocytopenia induced by high-dose melphalan appears to be reduced by the subsequent administration of GM-CSF to times which are at least as short as have been reported in historical series which have used autologous bone marrow rescue.

Перевод полного текста: Перевод в очереди

Читать найденный полный текст

https://creativecommons.org/licenses/by/4.0/ This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .

Antman K. S. Griffin J. D. Elias A. Socinski M. A. Ryan L. Cannistra S. A. Oette D. Whitley M. Frei E. 3rd Schnipper L. E. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. 319 10 8 9 1988 593 598 N Engl J Med 3045544 10.1056/NEJM198809083191001

Ardiet C. Tranchand B. Biron P. Rebattu P. Philip T. Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases. 16 3 1986 300 305 Cancer Chemother Pharmacol 3516430 10.1007/BF00293997

Bonadonna G. Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. 304 1 1 1 1981 10 15 N Engl J Med 7432433 10.1056/NEJM198101013040103

Brandt S. J. Peters W. P. Atwater S. K. Kurtzberg J. Borowitz M. J. Jones R. B. Shpall E. J. Bast R. C. Jr Gilbert C. J. Oette D. H. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. 318 14 7 4 1988 869 876 N Engl J Med 3281007 10.1056/NEJM198804073181401

Bronchud M. H. Howell A. Crowther D. Hopwood P. Souza L. Dexter T. M. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. 60 1 7 1989 121 125 Br J Cancer PMC2247341 2478178 10.1038/bjc.1989.234

Bronchud M. H. Scarffe J. H. Thatcher N. Crowther D. Souza L. M. Alton N. K. Testa N. G. Dexter T. M. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. 56 6 12 1987 809 813 Br J Cancer PMC2002403 2829955 10.1038/bjc.1987.295

Cornbleet M. A. McElwain T. J. Kumar P. J. Filshie J. Selby P. Carter R. L. Hedley D. W. Clark M. L. Millar J. L. Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. 48 3 9 1983 329 334 Br J Cancer PMC2011461 6351883 10.1038/bjc.1983.196

Corringham R. Gilmore M. Prentice H. G. Boesen E. High-dose melphalan with autologous bone marrow transplant. Treatment of poor prognosis tumors. 52 10 15 11 1983 1783 1787 Cancer 6354413 10.1002/1097-0142(19831115)52:10<1783::aid-cncr2820521004>3.0.co;2-h

Davis H. L. Chemotherapy of large bowel cancer. 50 11 Suppl 1 12 1982 2638 2646 Cancer 6215979

DeVita V. T. Dose-response is alive and well. 4 8 8 1986 1157 1159 J Clin Oncol 3525764 10.1200/JCO.1986.4.8.1157

Ekert H. Ellis W. M. Waters K. D. Tauro G. P. Autologous bone marrow rescue in the treatment of advanced tumors of childhood. 49 3 1 2 1982 603 609 Cancer 7037150 10.1002/1097-0142(19820201)49:3<603::aid-cncr2820490334>3.0.co;2-h

Frei E. 3rd Antitumor agents--dose response curve clinical and experimental considerations. 7 Suppl 5 1979 262 264 Exp Hematol 263243

Frei E. 3rd Canellos G. P. Dose: a critical factor in cancer chemotherapy. 69 4 10 1980 585 594 Am J Med 6999898 10.1016/0002-9343(80)90472-6

Hartmann O. Kalifa C. Benhamou E. Patte C. Flamant F. Jullien C. Beaujean F. Lemerle J. Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation. 16 2 1986 165 169 Cancer Chemother Pharmacol 3512113 10.1007/BF00256169

Henderson I. C. Hayes D. F. Gelman R. Dose-response in the treatment of breast cancer: a critical review. 6 9 9 1988 1501 1515 J Clin Oncol 3047340 10.1200/JCO.1988.6.9.1501

Lazarus H. M. Herzig R. H. Graham-Pole J. Wolff S. N. Phillips G. L. Strandjord S. Hurd D. Forman W. Gordon E. M. Coccia P. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. 1 6 6 1983 359 367 J Clin Oncol 6366139 10.1200/JCO.1983.1.6.359

Leff R. S. Thompson J. M. Johnson D. B. Mosley K. R. Daly M. B. Knight W. A. 3rd Ruxer R. L. Jr Messerschmidt G. L. Phase II trial of high-dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma. 4 11 11 1986 1586 1591 J Clin Oncol 3534154 10.1200/JCO.1986.4.11.1586

Lieschke G. J. Maher D. Cebon J. O'Connor M. Green M. Sheridan W. Boyd A. Rallings M. Bonnem E. Metcalf D. Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. 110 5 1 3 1989 357 364 Ann Intern Med 2644886 10.7326/0003-4819-110-5-357

McElwain T. J. Hedley D. W. Gordon M. Y. Jarman M. Millar J. L. Pritchard J. High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. 7 Suppl 5 1979 360 371 Exp Hematol 400698

Metcalf D. The granulocyte-macrophage colony-stimulating factors. 229 4708 5 7 1985 16 22 Science 2990035 10.1126/science.2990035

Morstyn G. Campbell L. Souza L. M. Alton N. K. Keech J. Green M. Sheridan W. Metcalf D. Fox R. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. 1 8587 26 3 1988 667 672 Lancet 2895212 10.1016/s0140-6736(88)91475-4

O'Bryan R. M. Baker L. H. Gottlieb J. E. Rivkin S. E. Balcerzak S. P. Grumet G. N. Salmon S. E. Moon T. E. Hoogstraten B. Dose response evaluation of adriamycin in human neoplasia. 39 5 5 1977 1940 1948 Cancer 858124 10.1002/1097-0142(197705)39:5<1940::aid-cncr2820390505>3.0.co;2-0

Selby P. J. McElwain T. J. Nandi A. C. Perren T. J. Powles R. L. Tillyer C. R. Osborne R. J. Slevin M. L. Malpas J. S. Multiple myeloma treated with high dose intravenous melphalan. 66 1 5 1987 55 62 Br J Haematol 3593657 10.1111/j.1365-2141.1987.tb06890.x

Steward W. P. Scarffe J. H. Austin R. Bonnem E. Thatcher N. Morgenstern G. Crowther D. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study. 59 1 1 1989 142 145 Br J Cancer PMC2246969 2667607 10.1038/bjc.1989.28

Vadhan-Raj S. Keating M. LeMaistre A. Hittelman W. N. McCredie K. Trujillo J. M. Broxmeyer H. E. Henney C. Gutterman J. U. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. 317 25 17 12 1987 1545 1552 N Engl J Med 3500414 10.1056/NEJM198712173172501

Vincent M. D. Powles T. J. Coombes R. C. McElwain T. J. Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy. 21 3 1988 255 260 Cancer Chemother Pharmacol 3282709 10.1007/BF00262781